Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease

Area of Science:

• Rheumatology and Pulmonology
• Translational Medicine
• Biomarker Discovery

Background:

• Systemic sclerosis (SSc) is a rare autoimmune disease with significant morbidity and mortality.
• Interstitial lung disease (ILD) is the primary cause of death in SSc patients.
• Current management of SSc-ILD faces challenges in predicting disease progression and designing effective clinical trials.

Purpose of the Study:

• To review the current status of personalized medicine in SSc-ILD.
• To explore future directions for personalized medicine in SSc-ILD.
• To discuss the application of personalized medicine in clinical trial design for SSc-ILD.

Main Methods:

• Narrative review of existing literature.
• Analysis of current therapeutic approaches and clinical trial designs.
• Identification of potential biomarkers for disease assessment.

Main Results:

• Personalized medicine approaches are crucial for addressing unmet needs in SSc-ILD.
• Serum, radiologic, and novel biomarkers show promise for assessing disease activity and treatment response.
• Personalized medicine can facilitate earlier diagnosis, disease stratification, and prognostication.

Conclusions:

• Personalized medicine holds significant potential to improve outcomes for SSc-ILD patients.
• Biomarker-driven strategies are key to advancing personalized care in SSc-ILD.
• Personalized medicine can enhance the design and efficiency of clinical trials for SSc-ILD.